SCHEMBL14474182

SCHEMBL14474182

CNc1nc(-c2ccccn2)nc2c(OC)cc(-c3ccc(F)cc3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 2/20 0.47
▸ ABCG2 Q9UNQ0 2/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ LMNA P02545 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ HTT P42858 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ PPP1CA P62136 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ METAP2 P50579 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474188 0.94 ABCB1 (0.47) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL16185130 0.91 ABCG2 (0.45) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL14474198 0.90 S1PR1 (0.46) ABCB1ABCG2SMN1; SMN2LMNAKDM4E
SCHEMBL14474671 0.89 L3MBTL1 (0.47) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL16185151 0.89 L3MBTL1 (0.45) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL14474206 0.89 CYP1A2 (0.43) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL16185123 0.88 LMNA (0.46) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL14474189 0.86 SCN9A (0.40) SMN1; SMN2ALDH1A1LMNAKDM4ECYP1A2
SCHEMBL14474196 0.86 KDM4E (0.39) ABCB1ABCG2SMN1; SMN2ALDH1A1LMNA
SCHEMBL14474183 0.86 KIT (0.39) SMN1; SMN2ALDH1A1LMNAKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ABCB1 3803/4885ABCG2 1597/4885SMN1; SMN2 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback